471 related articles for article (PubMed ID: 12509398)
1. Postmenopausal hormone therapy and change in mammographic density.
Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
[TBL] [Abstract][Full Text] [Related]
2. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
3. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
5. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
Byrne C; Ursin G; Martin CF; Peck JD; Cole EB; Zeng D; Kim E; Yaffe MD; Boyd NF; Heiss G; McTiernan A; Chlebowski RT; Lane DS; Manson JE; Wactawski-Wende J; Pisano ED
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376149
[TBL] [Abstract][Full Text] [Related]
6. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
[TBL] [Abstract][Full Text] [Related]
7. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
8. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
9. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
10. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.
Crandall CJ; Aragaki AK; Cauley JA; McTiernan A; Manson JE; Anderson GL; Wactawski-Wende J; Chlebowski RT
Breast Cancer Res Treat; 2012 Feb; 131(3):969-79. PubMed ID: 21979747
[TBL] [Abstract][Full Text] [Related]
11. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
[TBL] [Abstract][Full Text] [Related]
12. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
13. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
[TBL] [Abstract][Full Text] [Related]
14. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy.
Crandall CJ; Guan M; Laughlin GA; Ursin GA; Stanczyk FZ; Ingles SA; Barrett-Connor E; Greendale GA
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1674-81. PubMed ID: 18628419
[TBL] [Abstract][Full Text] [Related]
15. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
16. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
19. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.
McTiernan A; Chlebowski RT; Martin C; Peck JD; Aragaki A; Pisano ED; Wang CY; Johnson KC; Manson JE; Wallace RB; Vitolins MZ; Heiss G
J Clin Oncol; 2009 Dec; 27(36):6135-43. PubMed ID: 19901118
[TBL] [Abstract][Full Text] [Related]
20. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
Koh KK; Jin DK; Yang SH; Lee SK; Hwang HY; Kang MH; Kim W; Kim DS; Choi IS; Shin EK
Circulation; 2001 Apr; 103(15):1961-6. PubMed ID: 11306524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]